No Data
Zhejiang jingxin pharmaceutical (002020.SZ): The enteric-coated capsules for rehabilitation are currently nearing the end of Phase II clinical trials.
Glemanet December 3rd | zhejiang jingxin pharmaceutical (002020.SZ) stated on the investor interaction platform on December 3rd that the recovery new enteroic capsule is currently in the late stage of phase II clinical trials, and the company will proceed with the phase III clinical trials of this variety as soon as possible after the completion of phase II according to plan.
Are Robust Financials Driving The Recent Rally In Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Stock?
Zhejiang Jingxin Pharmaceutical's Insomnia Drug Added to National Medical Insurance Catalog
zhejiang jingxin pharmaceutical (002020.SZ): Dapoxetine capsules included in the national medical insurance catalog.
On November 28, Ge Long Hui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that recently, according to the notification published by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security, titled "Notice on the Issuance of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2024)" (Medical Insurance Fa [2024] No. 33) (hereinafter referred to as "the Notice"), that the Class 1 innovative drug Didasun Capsule (trademarked as "Jingnuoning", specification of 2.5mg) has been included in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog through national insurance negotiations.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The national negotiation work for Didasun capsules has been completed.
Gelonghui November 27th, zhejiang jingxin pharmaceutical (002020.SZ) stated on the investor interaction platform that the negotiations on Detasini capsules have been completed, and the company will announce the negotiation results according to the requirements of information disclosure rules.
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Strong Profits May Be Masking Some Underlying Issues
Zhejiang Jingxin Pharmaceutical (SZSE:002020) Jumps 5.8% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
